Indivior Pharmaceuticals, Inc.NASDAQ: INDV

Shareholders Approve Proposed Merger with Supernus

· Issued by Indivior Pharmaceuticals, Inc.

Summary by 6ix AI

On October 15, 2026, Indivior Pharmaceuticals' shareholders approved the proposed all-stock merger of equals with Supernus Pharmaceuticals, Inc., with 94% of votes cast in favor.

Key details

  • The merger was announced in August 2026.
  • After closing, the combined company will operate as Supernus, Inc. and trade on Nasdaq under the ticker symbol "SUPN."
  • The companies say the combined business will focus on central nervous system diseases, meaning conditions of the brain and spinal cord.

What’s still pending

  • The transaction is expected to close on November 2, 2026.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/indivior-pharmaceuticals-shareholders-approve-proposed-merger-with-supernus

Watch Indivior Pharmaceuticals' latest callIndivior Pharmaceuticals (NASDAQ:INDV) Q2 2026 Earnings Call · Replay · Aug 3Read the transcript of Indivior Pharmaceuticals (NASDAQ:INDV) Q2 2026 Earnings Call

Shareholders support combination to create a leading, diversified CNS-focused biopharmaceutical company

On October 15, 2026, Indivior's shareholders approved the proposed all-stock merger of equals with Supernus Pharmaceuticals, Inc. The proposal received strong support, with 94% of votes cast in favor of the transaction.

Shareholder approval marks an important milestone toward completing the merger, which was announced in August 2026. The transaction is expected to close on November 2, 2026. Following closing, the combined company will operate as Supernus, Inc., and trade on Nasdaq under the ticker symbol "SUPN."

The combination will bring together two complementary organizations to create a leading, diversified and scaled biopharmaceutical company focused on central nervous system diseases. Together, the companies will be positioned to build on their respective strengths, expand their impact for patients, and create long-term value for shareholders.

For Further Information

Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com

Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-mail: Indiviormediacontacts@indivior.com

Indivior Pharmaceuticals, Inc. on 6ix

Earlier from Indivior Pharmaceuticals

Later from Indivior Pharmaceuticals

All Indivior Pharmaceuticals news releases